Trials / Unknown
UnknownNCT00032279
Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease
A Phase II, Multicenter Clinical Trial Evaluating the Use of Humanized Monoclonal Anti-CD3 Antibody Visilizumab(Nuvion) as Second-line Therapy for Glucocorticoid-Refractory, Acute Graft-Versus-Host Disease
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (planned)
- Sponsor
- Fred Hutchinson Cancer Center · Academic / Other
- Sex
- All
- Age
- 0 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this phase II study is to evaluate an investigational monoclonal antibody for the treatment of glucocorticoid-refractory Graft Versus Host Disease (GVHD). Patients diagnosed with GVHD who have not responded satisfactorily to, or are intolerant of, treatment with standard agents will be considered for entry. Patients will be allowed to continue on their other immunosuppressive drugs at stable doses during the trial. The research is being conducted at up to 20 clinical research sites in the US.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Visilizumab |
Timeline
- Start date
- 2002-03-01
- First posted
- 2002-03-18
- Last updated
- 2005-06-24
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00032279. Inclusion in this directory is not an endorsement.